MedTrace Logo

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

NCT00186342 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-12-17

No results posted yet for this study

Summary

The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).

Conditions

  • Acute Disease
  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Chronic
  • Myeloproliferative Disorders
  • Blood and Marrow Transplant (BMT)
  • Myelodysplastic Syndromes (MDS)
  • Leukemia

Interventions

PROCEDURE

ablative allogeneic hematopoietic cell transplantation

Sponsors & Collaborators

Principal Investigators

  • Robert S Negrin · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
51 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-09-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186342 on ClinicalTrials.gov